Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

Inclusion Criteria

• •1\) Treatment in Peking University People's Hospital for radical resection of breast cancer and had hospitalization records;
• •2\) Postoperative pathology confirmed invasive breast cancer, and the pathological stage was T1c, N0, HER2 positive, with other high-risk factors (G3, or hormone receptor negative); Or the pathological stage is T2, N0, and there are no high-risk factors (G3, or hormone receptor negative);
• •3)Signed an agreement to participate in the PKUPH Breast Disease Cohort study at Peking University People's Hospital.